KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Depreciation & Amortization - TotalEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Non-Controlling InterestsInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

National Health Investors (NHI) EBITDA (2016 - 2022)

National Health Investors filings provide 14 years of EBITDA readings, the most recent being $8.2 million for Q1 2022.

  • On a quarterly basis, EBITDA fell 77.81% to $8.2 million in Q1 2022 year-over-year; TTM through Mar 2022 was $132.2 million, a 33.16% decrease, with the full-year FY2021 number at $8.2 million, down 77.81% from a year prior.
  • EBITDA hit $8.2 million in Q1 2022 for National Health Investors, down from $41.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $62.4 million in Q3 2019 to a low of $8.2 million in Q1 2022.
  • Median EBITDA over the past 5 years was $40.4 million (2018), compared with a mean of $41.5 million.
  • Biggest five-year swings in EBITDA: skyrocketed 50.81% in 2020 and later crashed 77.81% in 2022.
  • National Health Investors' EBITDA stood at $59.1 million in 2018, then increased by 5.61% to $62.4 million in 2019, then decreased by 26.63% to $45.8 million in 2020, then decreased by 10.58% to $41.0 million in 2021, then plummeted by 79.88% to $8.2 million in 2022.
  • The last three reported values for EBITDA were $8.2 million (Q1 2022), $41.0 million (Q2 2021), and $37.2 million (Q1 2021) per Business Quant data.